Bioformulative Concepts on Intracellular Organ Specific Bioavailability

References

• Mateus A Treyer A Wegler C Karlgren M Matsson P Artursson P . Intracellular drug bioavailability: a new predictor of system dependent drug disposition. Sci. Rep.7, 43047 (2017).
   PubMed Web of Science ®Google Scholar
• Stepensky D . Quantitative aspects of intracellularly-targeted drug delivery. Pharm. Res.27 (12), 2776–2280 (2010).
   PubMed Web of Science ®Google Scholar
• El-Kattan AF . Oral Bioavailability Assessment: Basics and Strategies for Drug Discovery and Development. John Wiley & Sons, USA (2017).
   Google Scholar
• Matsuda Y Konno Y Satsukawa M et al. Assessment of intestinal availability of various drugs in oral absorption process using portal vein cannulated rats. 40 (12), 2231–2238 (2012).
   Google Scholar
• Kang JS Lee MH . Overview of therapeutic drug monitoring. Korean J. Intern. Med.24 (1), 1 (2009).
   PubMedGoogle Scholar
• Meibohm B Derendorf H . Pharmacokinetic/pharmacodynamic studies in drug product development. J. Pharm. Sci.91 (1), 18–31 (2002).
   PubMed Web of Science ®Google Scholar
• Hamidi M Azadi A Rafiei P Ashrafi H . A pharmacokinetic overview of nanotechnology-based drug delivery systems: an ADME-oriented approach. Crit. Rev. Ther. Drug Carrier Syst.30 (5), 435–467 (2013).
   PubMed Web of Science ®Google Scholar
• Fuller MAA . Bioavailability–a brief history. Presented at : Proceedings of the 9th International Symposium on Digestive Physiology in Pigs. 1, 183–198 (2003).
   Google Scholar
• Chow SC Liu JP . Design and Analysis of Bioavailability and Bioequivalence Studies. Chapman and Hall/CRC, London, New York (2008).
   Google Scholar
• Jambhekar Sunil S Breen Philip J . Basic Pharmacokinetics Vol. 76. Pharmaceutical Press, London, UK (2009).
   Google Scholar
• Food and Drug Administration . Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products–general considerations. US Food and Drug Administration, Washington, DC, USA (2003).
   Google Scholar
• Central Drugs Standard Control Organization . Guidance for Bioavailability and Bioequivalence Studies. Central Drugs Standard Control Organization, New Delhi (2015).
   Google Scholar
• Committee for Medicinal Products for Human Use . Guideline on the Investigation of Bioequivalence. European Medicines Agency, London, UK (2010).
   Google Scholar
• Ahmed TA . Pharmacokinetics of drugs following IV Bolus, IV infusion, and oral administration. In : Basic Pharmacokinetic Concepts and Some Clinical Applications. InTech, London UK (2015).
   Google Scholar
• Aungst BJ . Optimizing oral bioavailability in drug discovery: an overview of design and testing strategies and formulation options. J. Pharm. Sci.106 (4), 921–929 (2017).
   PubMed Web of Science ®Google Scholar
• Burton PS Goodwin JT Vidmar TJ Amore BM . Predicting drug absorption: how nature made it a difficult problem. J. Pharmacol. Exp. Ther.303 (3), 889–895 (2002).
   PubMed Web of Science ®Google Scholar
• Hurst S Loi CM Brodfuehrer J El-Kattan A . Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans. Expert. Opin. Drug Metab. Toxicol.3 (4), 469–489 (2007).
   PubMed Web of Science ®Google Scholar
• Lawrence XY Lipka E Crison JR Amidon GL . Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv. Drug. Deliv. Rev.19 (3), 359–376 (1996).
   PubMed Web of Science ®Google Scholar
• Gavhane YN Yadav AV . Loss of orally administered drugs in GI tract. Saudi Pharm. J.20 (4), 331–344 (2012).
   PubMed Web of Science ®Google Scholar
• Dahan A Miller JM . The solubility–permeability interplay and its implications in formulation design and development for poorly soluble drugs. AAPS J.14 (2), 244–251 (2012).
   PubMed Web of Science ®Google Scholar
• Lipinski CA Lombardo F Dominy BW Feeney PJ . Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev.23 (1–3), 3–25 (1997).
   Web of Science ®Google Scholar
• Liu S Tam D Chen X Pang KS . P-Glycoprotein and an unstirred water layer barring digoxin absorption by the perfused rat small intestine preparation: induction studies with pregnenolone-16α-carbonitrile (PCN). Drug Metab. Dispos.34 (9), 1468–1479 (2006).
   PubMed Web of Science ®Google Scholar
• Stanfield CL . Principles of Human Physiology. Pearson Higher Ed., USA (2012).
   Google Scholar
• Menard S Cerf-Bensussan N Heyman M . Multiple facets of intestinal permeability and epithelial handling of dietary antigens. Mucosal. Immunol.3 (3), 247 (2010).
   PubMed Web of Science ®Google Scholar
• Avdeef A . Absorption and Drug Development: Solubility, Permeability, and Charge State. John Wiley & Sons, USA (2012).
   Google Scholar
• Lawler JW Slayter HS Coligan JE . Isolation and characterization of a high molecular weight glycoprotein from human blood platelets. J. Biol. Chem.253 (23), 8609–8616 (1978).
   PubMed Web of Science ®Google Scholar
• Chiba H Osanai M Murata M Kojima T Sawada N . Transmembrane proteins of tight junctions. Biochim. Biophys. Acta1778 (3), 588–600 (2008).
   PubMed Web of Science ®Google Scholar
• Elliott RL Amidon GL Lightfoot EN . A convective mass transfer model for determining intestinal wall permeabilities: laminar flow in a circular tube. J. Theor. Biol.87 (4), 757–771 (1980).
   PubMed Web of Science ®Google Scholar
• Chiou WL . Effect of ‘unstirred’ water layer in the intestine on the rate and extent of absorption after oral administration. Biopharm. Drug Dispos.15 (8), 709–717 (1994).
   PubMed Web of Science ®Google Scholar
• Smithson KW Millar DB Jacobs LR Gray GM . Intestinal diffusion barrier: unstirred water layer or membrane surface mucous coat?. Science214 (4526), 1241–1244 (1981).
   PubMed Web of Science ®Google Scholar
• Loftsson T . Drug permeation through biomembranes: cyclodextrins and the unstirred water layer. Die Pharmazie.67 (5), 363–370 (2012).
   PubMed Web of Science ®Google Scholar
• Rothblat GH Mahlberg FH Johnson WJ Phillips MC . Apolipoproteins, membrane cholesterol domains, and the regulation of cholesterol efflux. J. Lipid. Res.33 (8), 1091–1097 (1992).
   PubMed Web of Science ®Google Scholar
• Seithel A Karlsson J Hilgendorf C Björquist A Ungell AL . Variability in mRNA expression of ABC-and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells. Eur. J. Pharm. Sci.28 (4), 291–299 (2006).
   PubMed Web of Science ®Google Scholar
• Tsuji A Tamai I . Carrier-mediated intestinal transport of drugs. Pharm. Res.13 (7), 63–77 (1996).
   Web of Science ®Google Scholar
• Dean M Allikmets R . Complete characterization of the human ABC gene family. J. Bioenerg. Biomembr.33 (6), 475–479 (2001).
   PubMed Web of Science ®Google Scholar
• Suzuki H Sugiyama Y . Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur. J. Pharm. Sci.12 (1), 3–12 (2000).
   PubMed Web of Science ®Google Scholar
• Kwan KC . Oral bioavailability and first-pass effects. Drug Metab. Dispos.25 (12), 1329–1336 (1997).
   PubMed Web of Science ®Google Scholar
• Burroughs AK . The hepatic artery, portal venous system and portal hypertension: the hepatic veins and liver in circulatory failure. In : Sherlock's Diseases of the Liver and Biliary System (Twelfth Edition, Chapter 9). DooleyJSLokASFBurroughsAKJennyHE ( Eds). Wiley, London, UK, 152–209 (2011).
   Google Scholar
• Ramaiah SK Banerjee A . Liver toxicity of chemical warfare agents. In : Handbook of Toxicology of Chemical Warfare Agents. Academic Press, Elsevier Health Sciences, USA, 549–560 (2009).
   Google Scholar
• Washabau RJ Day MJ . Canine and Feline Gastroenterology–E-Book. Elsevier Health Sciences, USA (2012).
   Google Scholar
• Iwatsubo T Hirota N Ooie T et al. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther.73 (2), 147–171 (1997).
   PubMed Web of Science ®Google Scholar
• Nagar S Argikar UA Tweedie DJ . Enzyme kinetics in drug metabolism: fundamentals and applications. In : Enzyme Kinetics in Drug Metabolism. Humana Press, Totowa, N.J.S., 1–6 (2014).
   Google Scholar
• Ridgway D Tuszynski JA Tam YK . Reassessing models of hepatic extraction. J. Biol. Phys.29 (1), 1–21 (2003).
   PubMed Web of Science ®Google Scholar
• Thummel KE Kunze KL Shen DD . Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv. Drug Deliv. Rev.27 (2–3), 99–127 (1997).
   PubMed Web of Science ®Google Scholar
• Shargel L Andrew BC Wu-Pong S . Applied Biopharmaceutics & Pharmacokinetics. Appleton & Lange, CA, USA (1999).
   Google Scholar
• Pond SM Tozer TN . First-pass elimination basic concepts and clinical consequences. Clin. Pharmacokinet.9 (1), 1–25 (1984).
   PubMed Web of Science ®Google Scholar
• Callaghan R Luk F Bebawy M . Inhibition of the multidrug resistance P-glycoprotein; time for a change of strategy?. Drug Metabol. Dispos.42 (4), 623–631 (2014).
   PubMed Web of Science ®Google Scholar
• Hoosain FG Choonara YE Tomar LK et al. Bypassing P-glycoprotein drug efflux mechanisms: possible applications in pharmacoresistant schizophrenia therapy. BioMed. Res. Int.2015, 484963 (2015).
   PubMed Web of Science ®Google Scholar
• Russel FG . Transporters: importance in drug absorption, distribution, and removal. In : Enzyme-and transporter-based drug-drug interactions. Springer, NY, USA, 27–49 (2010).
   Google Scholar
• Yin N Brimble MA Harris PW Wen J . Enhancing the oral bioavailability of peptide drugs by using chemical modification and other approaches. Med. Chem.4, 763–769 (2014).
   Google Scholar
• Drug Distribution to Tissues . ByJenniferLE, PharmD, MAS, BCPS-ID, FIDSA, FCCP, FCSHP, Professor of Clinical Pharmacy and Director of Experiential Education in Los Angeles, Skaggs School of Pharmacy and Pharmaceutical Sciences. University of California San Diego, CA, USA (2018).
   Google Scholar
• Koda-Kimble MA . Koda-Kimble and Young's applied therapeutics: the clinical use of drugs. Lippincott Williams & Wilkins, USA (2012).
   Google Scholar
• Gonzalez D Schmidt S Derendorf H . Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents. Clin. Microbiol. Rev.26 (2), 274–288 (2013).
   PubMed Web of Science ®Google Scholar
• Klotz U . Pathophysiological and disease-induced changes in drug distribution volume: pharmacokinetic implications. Clin. Pharmacokinet.1 (3), 204–218 (1976).
   PubMedGoogle Scholar
• Mateus A Gordon LJ Wayne GJ et al. Prediction of intracellular exposure bridges the gap between target-and cell-based drug discovery. Proc. Natl Acad. Sci. USA114 (30), E6231-9 (2017).
   Web of Science ®Google Scholar
• Chien HC Zur AA Maurer TS et al. Rapid method to determine intracellular drug concentrations in cellular uptake assays: application to metformin in organic cation transporter 1-transfected human embryonic kidney 293 Cells. Drug Metab. Dispos.44, 356–364 (2016).
   PubMed Web of Science ®Google Scholar
• Morgan Edward T Lee Choon-Myung Nyagode Beatrice A . Regulation of Drug Metabolizing Enzymes and Transporters in Infection, Inflammation, and Cancer. Encyclopedia of Drug Metabolism and Interactions. Wiley, USA, 1–45 (2011).
   Google Scholar
• Zhuanga Xiaomei Lub Chuang . PBPK modeling and simulation in drug research and development. Acta Pharm. Sin. B.6 (5), 430–440 (2016).
   PubMed Web of Science ®Google Scholar
• Jones HM Rowland-Yeo K . Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics. Syst. Pharmacol.2 (8), 1–2 (2013).
   Google Scholar
• Kuepfer L Niederalt C Wendl T et al. Applied concepts in PBPK modeling: how to build a PBPK/PD model. CPT. Pharmacometrics Syst. Pharmacol.5 (10), 516–531 (2016).
   PubMedGoogle Scholar
• Poirier A Funk C Lavé T . Role of PBPK modeling in drug discovery: opportunities and limitations. In : PAMM: Proceedings in Applied Mathematics and Mechanics. Wiley-Vch Verlag, Berlin, Germany, 7 (1), 1121907–1121908 (2007).
   Google Scholar
• Whiting B Kelman AW Grevel J . Population pharmacokinetics theory and clinical application. Clin. Pharmacokinet.11 (5), 387–401 (1986).
   PubMed Web of Science ®Google Scholar
• Vozeh S Maitre PO Stanski DR . Evaluation of population (NONMEM) pharmacokinetic parameter estimates. J. Pharmacokinet. Biopharm.18 (2), 161–173 (1990).
   PubMedGoogle Scholar
• Samara E Granneman R . Role of population pharmacokinetics in drug development. Clin. Pharmacokinet.32 (4), 294–312 (1997).
   PubMed Web of Science ®Google Scholar
• Teuscher KB Zhang M Ji H . A versatile method to determine the cellular bioavailability of small-molecule inhibitors. J. Med. Chem.60 (1), 157–169 (2017).
   PubMed Web of Science ®Google Scholar
• Ponchel G Irache JM . Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv. Drug Deliv. Rev.34 (2–3), 191–219 (1998).
   PubMed Web of Science ®Google Scholar
• Treuel L Jiang X Nienhaus GU . New views on cellular uptake and trafficking of manufactured nanoparticles. J. R. Soc. Interface.10 (82), 20120939 (2013).
   PubMed Web of Science ®Google Scholar
• Roger E Kalscheuer S Kirtane A et al. Folic acid functionalized nanoparticles for enhanced oral drug delivery. Mol. Pharm.9 (7), 2103–2110 (2012).
   PubMed Web of Science ®Google Scholar
• Fadeel B Pietroiusti A Shvedova AA . Adverse Effects of Engineered Nanomaterials: Exposure, Toxicology, and Impact on Human Health. Academic Press, London, UK (2017).
   Google Scholar
• Lundquist P Artursson P . Oral absorption of peptides and nanoparticles across the human intestine: opportunities, limitations and studies in human tissues. Adv. Drug Deliv. Rev.106, 256–276 (2016).
   PubMed Web of Science ®Google Scholar
• Khan AA Mudassir J Mohtar N Darwis Y . Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. Int. J. Nanomed.8, 2733 (2013).
   PubMed Web of Science ®Google Scholar
• Florence AT Siepmann J . Modern Pharmaceutics Volume 1: Basic Principles and Systems. CRC Press, CA, USA (2009).
   Google Scholar
• Rizk ML Zou L Savic RM Dooley KE . Importance of drug pharmacokinetics at the site of action. Clin. Transl. Sci.10 (3), 133–142 (2017).
   PubMed Web of Science ®Google Scholar
• Bertol CD Oliveira PR Kuminek G Rauber GS Stulzer HK Silva MA . Increased bioavailability of primaquine using poly (ethylene oxide) matrix extended-release tablets administered to beagle dogs. Ann. Trop. Med. Parasitol.105, 475–484 (2011).
   PubMed Web of Science ®Google Scholar
• Padhye SG Nagarsenker Mangal S . Simvastatin solid lipid nanoparticles for oral delivery: formulation development and in vivo evaluation. Indian J. Pharm. Sci.75 (5), 591–598 (2013).
   PubMed Web of Science ®Google Scholar
• Huttunen KM Raunio H Rautio J . Prodrugs–from serendipity to rational design. Pharmacol. Rev.63 (3), 750771 (2011).
   PubMed Web of Science ®Google Scholar
• Ladenson PW Kristensen JD Ridgway EC et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N. Engl. J. Med.362, 906–1916 (2010).
   PubMed Web of Science ®Google Scholar
• Charmot D . Non-systemic drugs: a critical review. Curr. Pharm. Des.18 (10), 1434–1445 (2012).
   PubMed Web of Science ®Google Scholar
• Nutt D . GABA A receptors: subtypes, regional distribution, and function. J. Clin. Sleep Med.2 (02), S7–S11 (2006).
   PubMedGoogle Scholar
• Reddy LH Couvreur P . Nanotechnology for therapy and imaging of liver diseases. J. Hepatol.55 (6), 1461–1466 (2011).
   PubMed Web of Science ®Google Scholar
• Mueller M de la Peña A Derendorf H . Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob. Agents Chemother.48 (2), 369–377 (2004).
   PubMed Web of Science ®Google Scholar
• D'avolio A Pensi D Baietto L Di Perri G . Therapeutic drug monitoring of intracellular anti-infective agents. J. Pharm. Biomed. Anal.101, 183–193 (2014).
   PubMed Web of Science ®Google Scholar
• Leucuta SE . Subcellular drug targeting, pharmacokinetics and bioavailability. J. Drug Target.22 (2), 95–115 (2014).
   PubMed Web of Science ®Google Scholar
• Aljayyoussi G Jenkins VA Sharma R . Pharmacokinetic–pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment duration. Sci. Rep.107, 1–11 (2017).
   Google Scholar
• You JO Auguste DT . Nanocarrier cross-linking density and pH sensitivity regulate intracellular gene transfer. Nano. Lett.9, 4467–4473 (2009).
   PubMed Web of Science ®Google Scholar
• He C Hu Y Yin L Tang C Yin C . Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials.31 (13), 3657–3666 (2010).
   PubMed Web of Science ®Google Scholar
• Funato K Yoda R Kiwada H . Contribution of complement system on destabilization of liposomes composed of hydrogenated egg phosphatidylcholine in rat fresh plasma. Biochim. Biophys. Acta.1103 (2), 198–204 (1992).
   PubMedGoogle Scholar
• Wisse E Jacobs F Topal B Frederik P De Geest B . The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer. Gene Ther.15 (17), 1193 (2008).
   PubMed Web of Science ®Google Scholar
• Mishra N Yadav NP Rai VK et al. Efficient hepatic delivery of drugs: novel strategies and their significance. Biomed Res. Int.2013, 382184 (2013).
   PubMed Web of Science ®Google Scholar
• Ogawara KI Yoshida M Furumoto K et al. Uptake by hepatocytes and biliary excretion of intravenously administered polystyrene microspheres in rats. J. Drug Target7 (3), 213–221 (1999).
   PubMed Web of Science ®Google Scholar
• Harashima H Kiwada H . Liposomal targeting and drug delivery: kinetic consideration. Adv. Drug Deliv. Rev.19 (3), 425–444 (1996).
   Web of Science ®Google Scholar
• Park JH Lee S Kim JH Park K Kim K Kwon IC . Polymeric nanomedicine for cancer therapy. Prog. Polym. Sci.33 (1), 113–137 (2008).
   Web of Science ®Google Scholar
• Tian Q Zhang CN Wang XH et al. Glycyrrhetinic acid-modified chitosan/poly (ethylene glycol) nanoparticles for liver-targeted delivery. Biomaterials31 (17), 4748–4756 (2010).
   PubMed Web of Science ®Google Scholar
• Negishi M Irie A Nagata N Ichikawa A . Specific binding of glycyrrhetinic acid to the rat liver membrane. (BBA)-Biomembranes.1066 (1), 77–82 (1991).
   PubMedGoogle Scholar
• Geng YA Dalhaimer P Cai S et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat. Nanotechnol.2 (4), 249 (2007).
   PubMed Web of Science ®Google Scholar
• Banquy X Suarez F Argaw A et al. Effect of mechanical properties of hydrogel nanoparticles on macrophage cell uptake. Soft Matter.5, 3984–3991 (2009).
   Web of Science ®Google Scholar
• Janát-Amsbury MM Ray A Peterson CM Ghandehari H . Geometry and surface characteristics of gold nanoparticles influence their biodistribution and uptake by macrophages. Eur. J. Pharm. Biopharm.77 (3), 417–423 (2011).
   PubMed Web of Science ®Google Scholar
• Liu Z Cai W He L et al. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat. Nanotechnol.2 (1), 47 (2007).
   PubMed Web of Science ®Google Scholar
• Beningo KA Wang YL . Fc-receptor-mediated phagocytosis is regulated by mechanical properties of the target. J. Cell Sci.115 (4), 849–856 (2002).
   PubMed Web of Science ®Google Scholar
• Merkel TJ Jones SW Herlihy KP et al. Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles. Proc. Natl Acad. Sci. USA108 (2), 586–591 (2010).
   Web of Science ®Google Scholar
• Lück M Paulke BR Schröder W Blunk T Müller RH . Analysis of plasma protein adsorption on polymeric nanoparticles with different surface characteristics. J. Biomed. Mater. Res.39 (3), 478–485 (1998).
   PubMed Web of Science ®Google Scholar
• Adrian JE Kamps JA Scherphof GL et al. A novel lipid-based drug carrier targeted to the non-parenchymal cells, including hepatic stellate cells, in the fibrotic livers of bile duct ligated rats. Biochim. Biophys. Acta (BBA) Biomembranes.1768 (6), 1430–1439 (2007).
   PubMed Web of Science ®Google Scholar
• Cheng M He B Wan T . 5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model. Plos One7 (10), e47115 (2012).
   PubMed Web of Science ®Google Scholar
• Mori A Klibanov AL Torchilin VP Huang L . Influence of the steric barrier activity of amphipathic poly (ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo. FEBS Lett.284 (2), 263–266 (1991).
   PubMed Web of Science ®Google Scholar
• Dolman ME Harmsen S Storm G Hennink WE Kok RJ . Drug targeting to the kidney: advances in the active targeting of therapeutics to proximal tubular cells. Adv. Drug Deliv. Rev.62 (14), 1344–1357 (2010).
   PubMed Web of Science ®Google Scholar
• Zhou P Sun X Zhang Z . Kidney–targeted drug delivery systems. Acta. Pharm. Sin B.4 (1), 37–42 (2014).
   PubMed Web of Science ®Google Scholar
• Kaissling B Hegyi I Loffing J Le Hir M . Morphology of interstitial cells in the healthy kidney. Anat. Embryol. (Berl).193 (4), 303–318 (1996).
   PubMedGoogle Scholar
• Satchell SC Braet F . Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier. Am. J. Physiol. Ren. Physiol.296 (5), F947–F956 (2009).
   PubMed Web of Science ®Google Scholar
• Stan RV Kubitza M Palade GE . PV-1 is a component of the fenestral and stomatal diaphragms in fenestrated endothelia. Proc. Natl Acad. Sci. USA96 (23), 13203–13207 (1999).
   PubMed Web of Science ®Google Scholar
• Pavenstaädt H . Roles of the podocyte in glomerular function. Am. J. Physiol. Ren. Physiol.278 (2), F173–F179 (2000).
   PubMed Web of Science ®Google Scholar
• Schipper ML Iyer G Koh AL et al. Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small.5, 126–134 (2009).
   PubMed Web of Science ®Google Scholar
• Takakura Y Mahato RI Nishikawa M Hashida M . Control of pharmacokinetic profiles of drug–macromolecule conjugates. Adv. Deliv. Rev.19 (3), 377–399 (1996).
   Web of Science ®Google Scholar
• Dresser MJ Leabman MK Giacomini KM . Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. J. Pharm. Sci.90 (4), 397–421 (2001).
   PubMed Web of Science ®Google Scholar
• Christensen EI Verroust PJ Nielsen R . Receptor-mediated endocytosis in renal proximal tubule. Pflügers Archiv. Eur. J. Physiol.458 (6), 1039–1048 (2009).
   PubMed Web of Science ®Google Scholar
• Albrecht C Meijer DK Lebbe C et al. Targeting naproxen coupled to human serum albumin to nonparenchymal cells reduces endotoxin-induced mortality in rats with biliary cirrhosis. Hepatology26 (6), 1553–1559 (1997).
   PubMed Web of Science ®Google Scholar
• Haverdings RF Haas M Navis G et al. Renal targeting of captopril selectively enhances the intrarenal over the systemic effects of ACE inhibition in rats. Br. J. Pharmacol.136 (8), 1107–1116 (2002).
   PubMed Web of Science ®Google Scholar
• Yuan ZX Zhang ZR Zhu D et al. Specific renal uptake of randomly 50% N-acetylated low molecular weight chitosan. Mol. Pharm.6 (1), 305–314 (2008).
   Google Scholar
• Tuffin G Waelti E Huwyler J Hammer C Marti HP . Immunoliposome targeting to mesangial cells: a promising strategy for specific drug delivery to the kidney. J. Am. Soc. Nephrol.16 (11), 3295–3305 (2005).
   PubMed Web of Science ®Google Scholar
• Sarko D Georges RB . Kidney-specific drug delivery: review of opportunities, achievements, and challenges. J. Anal. Pharm. Res.2, 00033 (2016).
   Google Scholar
• van de Waterbeemd H Camenisch G Folkers G Chretien JR Raevsky OA . Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J. Drug Target.6 (2), 151–165 (1998).
   PubMed Web of Science ®Google Scholar
• Tamai I Tsuji A . Transporter-mediated permeation of drugs across the blood–brain barrier. J. Pharm. Sci.89 (11), 1371–1388 (2000).
   PubMed Web of Science ®Google Scholar
• Pathan SA Iqbal Z Zaidi S et al. CNS drug delivery systems: novel approaches. Recent Pat. Drug Deliv. Formul.3 (1), 71–89 (2009).
   PubMedGoogle Scholar
• Bellavance MA Blanchette M Fortin D . Recent advances in blood–brain barrier disruption as a CNS delivery strategy. AAPS J.10 (1), 166–177 (2008).
   PubMed Web of Science ®Google Scholar
• Masserini M . Nanoparticles for brain drug delivery. ISRN Bochem.2013, 18 (2013).
   Google Scholar
• Da Cruz MT Simões S de Lima MC . Improving lipoplex-mediated gene transfer into C6 glioma cells and primary neurons. Exp. Neurol.187 (1), 65–75 (2004).
   PubMed Web of Science ®Google Scholar
• Wang JX Sun X Zhang ZR . Enhanced brain targeting by synthesis of 3′, 5′-dioctanoyl-5-fluoro-2′-deoxyuridine and incorporation into solid lipid nanoparticles. Eur. J. Pharm. Biopharm.54 (3), 285–290 (2002).
   PubMed Web of Science ®Google Scholar
• Kannan S Dai H Navath RS et al. Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model. Sci. Transl. Med.4 (2012).
   PubMed Web of Science ®Google Scholar
• Bergen JM Pun SH . Analysis of the intracellular barriers encountered by nonviral gene carriers in a model of spatially controlled delivery to neurons. J. Gene Med.10 (2), 187–197 (2008).
   PubMed Web of Science ®Google Scholar
• Cheraghi M Negahdari B Daraee H Eatemadi A . Heart targeted nanoliposomal/nanoparticles drug delivery: an updated review. Biomed. Pharmaco. ther.86, 316–323 (2017).
   PubMed Web of Science ®Google Scholar
• Chanyshev B Shainberg A Isak A et al. Anti-ischemic effects of multivalent dendrimeric A3 adenosine receptor agonists in cultured cardiomyocytes and in the isolated rat heart. Pharmacol. Res.65 (3), 338–346 (2012).
   PubMed Web of Science ®Google Scholar
• Liu M Li M Wang G et al. Heart-targeted nanoscale drug delivery systems. J. Biomed. Nanotechnol.10 (9), 2038–2062 (2014).
   PubMed Web of Science ®Google Scholar